Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach

Abd El Razik, 2017, Benzodioxole–pyrazole hybrids as anti-inflammatory and analgesic agents with COX-1, 2/5-LOX inhibition and antioxidant potential, Arch. Pharm., 350, 10.1002/ardp.201700026 Abdelrahman, 2017, Synthesis, biological evaluation, docking study and ulcerogenicity profiling of some novel quinoline-2-carboxamides as dual COXs/LOX inhibitors endowed with anti-inflammatory activity, Eur. J. Med. Chem., 127, 972, 10.1016/j.ejmech.2016.11.006 Abou-Raya, 2006, Inflammation: a pivotal link between autoimmune diseases and atherosclerosis, Autoimmun. Rev., 5, 331, 10.1016/j.autrev.2005.12.006 Akhter, 2011, Synthesis and biological evaluation of 2, 5-disubstituted 1, 3, 4-oxadiazole derivatives with both COX and LOX inhibitory activity, J. Enzyme Inhib. Med. Chem., 26, 767, 10.3109/14756366.2010.550890 Aksakal, 2015, The study of dual COX-2/5-LOX inhibitors by using electronic-topological approach based on data on the ligand–receptor interactions, J. Mol. Graph. Model., 60, 79, 10.1016/j.jmgm.2015.06.006 Altavilla, 2009, Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages, Br. J. Pharmacol., 157, 1410, 10.1111/j.1476-5381.2009.00322.x Altavilla, 2012, Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia, Br. J. Pharmacol., 167, 95, 10.1111/j.1476-5381.2012.01969.x Alvaro-Gracia, 2004, Licofelone—clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis, Rheumatology, 43, i21, 10.1093/rheumatology/keh105 Anderson, 2008, Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis, Pharmacol. Rev., 60, 311, 10.1124/pr.108.00001 Anderson, 1990, Gastrointestinal (GI) profile of tepoxalin (TX), an orally active dual cyclooxygenase (CO)/lipoxygenase (LO) inhibitor with potent antiinflammatory activity, FASEB J., 4, A1122 Apostolidis, 2013, Synthesis and biological evaluation of some 5-arylidene-2-(1, 3-thiazol-2-ylimino)-1, 3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents, Bioorg. Med. Chem., 21, 532, 10.1016/j.bmc.2012.10.046 Araico, 2006, Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase, Life Sci., 78, 2911, 10.1016/j.lfs.2005.11.017 Araico, 2007, Evaluation of the anti-inflammatory and analgesic activity of Me-UCH9, a dual cyclooxygenase-2/5-lipoxygenase inhibitor, Life Sci., 80, 2108, 10.1016/j.lfs.2007.03.017 Argentieri, 1994, Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile, J. Pharmacol. Exp. Ther., 271, 1399 Barbey, 2002, Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor, Bioorg. Med. Chem. Lett., 12, 779, 10.1016/S0960-894X(02)00013-6 Barr, 1988, The in vitro 5-lipoxygenase and cyclo-oxygenase inhibitor L-652,343 does not inhibit 5-lipoxygenase in vivo in human skin, Br. J. Clin. Pharmacol., 25, 23, 10.1111/j.1365-2125.1988.tb03277.x Bertez, 1984, Dual inhibition of cyclooxygenase and lipoxygenase by 2-acetylthiophene 2-thiazolylhydrazone (CBS-1108) and effect on leukocyte migration in vivo, Biochem. Pharmacol., 33, 1757, 10.1016/0006-2952(84)90346-0 Blackburn, 1991, Inhibition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis, Arthritis Rheum., 34, 204, 10.1002/art.1780340212 Blackham, 1990, FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor, Agents Actions, 30, 432, 10.1007/BF01966309 Blobaum, 2007, Structural and functional basis of cyclooxygenase inhibition, J. Med. Chem., 50, 1425, 10.1021/jm0613166 Boschelli, 1992, Conversion of NSAIDS into balanced dual inhibitors of cyclooxygenase and 5-lipoxygenase, Bioorg. Med. Chem. Lett., 2, 69, 10.1016/S0960-894X(00)80657-5 Brash, 1997, Discovery of a second 15S-lipoxygenase in humans, Proc. Natl. Acad. Sci., 94, 6148, 10.1073/pnas.94.12.6148 Bresalier, 2005, Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N. Engl. J. Med., 352, 1092, 10.1056/NEJMoa050493 Cai, 2016, Discovery of novel hybrids of diaryl-1, 2, 4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy, Eur. J. Med. Chem., 108, 89, 10.1016/j.ejmech.2015.11.013 Canali, 2009, The anti-inflammatory pharmacology of Pycnogenol® in humans involves COX-2 and 5-LOX mRNA expression in leukocytes, Int. Immunopharmacol., 9, 1145, 10.1016/j.intimp.2009.06.001 Chakrin, 2012 Chen, 2006, Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs), Bioorg. Med. Chem., 14, 7898, 10.1016/j.bmc.2006.07.047 Chen, 2010, Discovery of 3-(4-bromophenyl)-6-nitrobenzo [1.3. 2] dithiazolium ylide 1, 1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also inhibits tumor necrosis factor-α production, Bioorg. Med. Chem., 18, 597, 10.1016/j.bmc.2009.12.008 Chowdhury, 2008, Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2 (1H) one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity, Bioorg. Med. Chem. Lett., 18, 6138, 10.1016/j.bmcl.2008.10.009 Chowdhury, 2009, Synthesis of 1-(methanesulfonyl-and aminosulfonylphenyl) acetylenes that possess a 2-(N-difluoromethyl-1, 2-dihydropyridin-2-one) pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity, Bioorg. Med. Chem. Lett., 19, 584, 10.1016/j.bmcl.2008.12.066 Chowdhury, 2009, Bioorg. Med. Chem. Lett., 19, 6855, 10.1016/j.bmcl.2009.10.083 Chowdhury, 2009, Synthesis of celecoxib analogues possessing a N-difluoromethyl-1, 2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity, J. Med. Chem., 52, 1525, 10.1021/jm8015188 Chowdhury, 2010, Synthesis and biological evaluation of indomethacin analogs possessing a N-difluoromethyl-1, 2-dihydropyrid-2-one ring system: a search for novel cyclooxygenase and lipoxygenase inhibitors, Bioorg. Med. Chem. Lett., 20, 5776, 10.1016/j.bmcl.2010.07.132 Clària, 2003, Cyclooxygenase-2 biology, Curr. Pharm. Des., 9, 2177, 10.2174/1381612033454054 Coussens, 2002, Inflammation and cancer, Nature, 420, 860, 10.1038/nature01322 Cusan, 2005, Synthesis and biological evaluation of new phenidone analogues as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitors, Il Farmaco, 60, 7, 10.1016/j.farmac.2004.09.002 de Gaetano, 2003, Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors, Trends Pharmacol. Sci., 24, 245, 10.1016/S0165-6147(03)00077-4 Deshmukh, 2013, Licofelone: a dual COX/5-LOX inhibitor attenuates intracerebroventricular streptozotocin-induced cognitive deficit, oxidative stress and neuro-inflammatory cytokines in rats, Alzheimers Dement., 9, P302, 10.1016/j.jalz.2013.05.619 Dinarello, 2010, Anti-inflammatory agents: present and future, Cell, 140, 935, 10.1016/j.cell.2010.02.043 Ding, 2011, Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors, Biomed Pharmacother, 65, 486, 10.1016/j.biopha.2011.06.009 Dogné, 2005, Adverse cardiovascular effects of the coxibs, J. Med. Chem., 48, 2251, 10.1021/jm0402059 Eleftheriou, 2012, Fragment-based design, docking, synthesis, biological evaluation and structure–activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors, Eur. J. Med. Chem., 47, 111, 10.1016/j.ejmech.2011.10.029 El-Miligy, 2017, New hybrid molecules combining benzothiophene or benzofuran with rhodanine as dual COX-1/2 and 5-LOX inhibitors: synthesis, biological evaluation and docking study, Bioorg. Chem., 72, 102, 10.1016/j.bioorg.2017.03.012 El-Miligy, 2017, New benzothiophene derivatives as dual COX-1/2 and 5-LOX inhibitors: synthesis, biological evaluation and docking study, Future Med. Chem., 9, 443, 10.4155/fmc-2016-0230 Funk, 2001, Prostaglandins and leukotrienes: advances in eicosanoid biology, Science, 294, 1871, 10.1126/science.294.5548.1871 Gautam, 2016, DuCLOX-2/5 inhibition: a promising target for cancer chemoprevention, Breast Cancer, 1 Ghatak, 2014, Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities, Bioorg. Med. Chem. Lett., 24, 317, 10.1016/j.bmcl.2013.11.015 Ghosh, 2015, The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update, Food Chem. Toxicol., 83, 111, 10.1016/j.fct.2015.05.022 Gilbert, 2011, The structure of human 5-lipoxygenase, Science, 331, 217, 10.1126/science.1197203 Gilbert, 2012, Conversion of human 5-lipoxygenase to a 15-lipoxygenase by a point mutation to mimic phosphorylation at Serine-663, FASEB J., 26, 3222, 10.1096/fj.12-205286 Gomes, 2012, Trihydroxyflavones with antioxidant and anti-inflammatory efficacy, Biofactors, 38, 378, 10.1002/biof.1033 Griswold, 1990, Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism, Agents Actions Suppl., 32, 113 Griswold, 1991, Pharmacology of the pyrroloimidazole, SK&F 105809—II: antiinflammatory activity and inhibition of mediator production in vivo, Biochem. Pharmacol., 42, 825, 10.1016/0006-2952(91)90042-4 Grosser, 2010, Emotion recollected in tranquility: lessons learned from the COX-2 saga, Annu. Rev. Med., 61, 17, 10.1146/annurev-med-011209-153129 Guttendorf, 1997, Multiple-dose pharmacokinetics of the antiinflammatory drug, CI-1004, in healthy subjects after 3-weeks of once-daily dosing, Pharmacol. Res., 14, A818 Guttendorf, 1997, Single-dose pharmacokinetics and dose proportionality of the antiinflammatory drug, CI-1004, in healthy subjects, Pharmacol. Res., 14, A818 Halsey, 1982, Benoxaprofen: side-effect profile in 300 patients, Br. Med. J. (Clin. Res. Ed.), 284, 1365, 10.1136/bmj.284.6326.1365 Hamer, 1996, Dibenzoxepinone hydroxylamines and hydroxamic acids: dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity, J. Med. Chem., 39, 246, 10.1021/jm950563z Harirforoosh, 2014, Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications, J. Pharm. Pharm. Sci., 16, 821, 10.18433/J3VW2F Hindson, 1982, Side effects of benoxaprofen, Br. Med. J. (Clin. Res. Ed.), 284, 1368, 10.1136/bmj.284.6326.1368 Horizoe, 1998, ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model, Inflamm. Res., 47, 375, 10.1007/s000110050347 Hyde, 2009, Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis, Int. Immunopharmacol., 9, 701, 10.1016/j.intimp.2009.02.003 Inagaki, 2000, Novel antiarthritic agents with 1, 2-isothiazolidine-1, 1-dioxide (γ-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase, J. Med. Chem., 43, 2040, 10.1021/jm9906015 Jahng, 2004, Simple aromatic compounds containing propenone moiety show considerable dual COX/5-LOX inhibitory activities, Bioorg. Med. Chem. Lett., 14, 2559, 10.1016/j.bmcl.2004.02.099 Janusz, 1998, New cyclooxygenase-2/5-lipoxygenase inhibitors. 1. 7-tert-butyl-2, 3-dihydro-3, 3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: discovery and variation of the 5-keto substituent, J. Med. Chem., 41, 1112, 10.1021/jm970679q Janusz, 1998, New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2, 3-dihydro-3, 3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations of the dihydrobenzofuran ring, J. Med. Chem., 41, 1124, 10.1021/jm970680p Janusz, 1998, New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3, 3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position, J. Med. Chem., 41, 3515, 10.1021/jm9802416 Jiang, 2014, Discovery of potential anti-inflammatory drugs: diaryl-1, 2, 4-triazoles bearing N-hydroxyurea moiety as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase, Org. Biomol. Chem., 12, 2114, 10.1039/c3ob41936c Kaur, 2012, Aspirin analogues as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, nitric oxide release, molecular modeling, and biological evaluation as anti-inflammatory agents, ChemMedChem, 7, 144, 10.1002/cmdc.201100460 Kilty, 1999, Differential characteristics of human 15-lipoxygenase isozymes and a novel splice variant of 15S-lipoxygenase, Eur. J. Biochem., 266, 83, 10.1046/j.1432-1327.1999.00818.x Kirchner, 1997, Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation, J. Pharmacol. Exp. Ther., 282, 1094 Kobe, 2013 Korotkova, 2014, Persisting eicosanoid pathways in rheumatic diseases, Nat. Rev. Rheumatol., 10, 229, 10.1038/nrrheum.2014.1 Kurumbail, 1996, Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents, Nature, 384, 644, 10.1038/384644a0 Lai, 2010, Synthesis and biological evaluation of 3-[4-(amino/methylsulfonyl) phenyl] methylene-indolin-2-one derivatives as novel COX-1/2 and 5-LOX inhibitors, Bioorg. Med. Chem. Lett., 20, 7349, 10.1016/j.bmcl.2010.10.056 Lamie, 2016, Novel N-substituted indole Schiff bases as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase enzymes: synthesis, biological activities in vitro and docking study, Eur. J. Med. Chem., 123, 803, 10.1016/j.ejmech.2016.08.013 Langhansova, 2017, Myrica rubra leaves as a potential source of a dual 5-LOX/COX inhibitor, Food Agric. Immunol., 28, 343, 10.1080/09540105.2016.1272554 Laufer, 1997, Synthesis and evaluation of a novel series of pyrrolizine derivatives as dual cyclooxygenase-1 and 5-lipoxygenase inhibitors, Arch. Pharm., 330, 307, 10.1002/ardp.19973300908 Laufer, 2003 Lee, 2006, Potent analgesic and anti-inflammatory activities of 1-furan-2-yl-3-pyridin-2-yl-propenone with gastric ulcer sparing effect, Biol. Pharm. Bull., 29, 361, 10.1248/bpb.29.361 Leval, 2002, New trends in dual 5-LOX/COX inhibition, Curr. Med. Chem., 9, 941, 10.2174/0929867024606713 Lewis, 1990, Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases, N. Engl. J. Med., 323, 645, 10.1056/NEJM199009063231006 Li, 2009, The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor, Eur. J. Pharmacol., 607, 244, 10.1016/j.ejphar.2009.02.032 Li, 2011, Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase, Bioorg. Med. Chem., 19, 2074, 10.1016/j.bmc.2011.01.043 Lino, 2017, Pharmacological evaluation and molecular docking of new di-tert-butylphenol compound, LQFM-091, a new dual 5-LOX/COX inhibitor, Eur. J. Pharm. Sci., 106, 231, 10.1016/j.ejps.2017.06.006 Lokwani, 2015, Structure based library design (SBLD) for new 1, 4-dihydropyrimidine scaffold as simultaneous COX-1/COX-2 and 5-LOX inhibitors, Bioorg. Med. Chem., 23, 4533, 10.1016/j.bmc.2015.06.008 Loomans, 1987, Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation Lucas, 2006, The role of inflammation in CNS injury and disease, Br. J. Pharmacol., 147, S232, 10.1038/sj.bjp.0706400 Lucido, 2016, Crystal structure of aspirin-acetylated human cyclooxygenase-2: insight into the formation of products with reversed stereochemistry, Biochemistry, 55, 1226, 10.1021/acs.biochem.5b01378 Mahshid, 2006 Malkowski, 2000, The productive conformation of arachidonic acid bound to prostaglandin synthase, Science, 289, 1933, 10.1126/science.289.5486.1933 Martel-Pelletier, 2003, Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs, Ann. Rheum. Dis., 62, 501, 10.1136/ard.62.6.501 Minutoli, 2015, A dual inhibitor of cyclooxygenase and 5-lipoxygenase protects against kainic acid-induced brain injury, NeuroMolecular Med., 17, 192, 10.1007/s12017-015-8351-0 Misra, 2013, Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan–CD44v6 pathway and inducing cytotoxicity in colon cancer cells, Bioorg. Med. Chem., 21, 2551, 10.1016/j.bmc.2013.02.033 Moreau, 2006, Synthesis and biological evaluation of acyclic triaryl (Z)-olefins possessing a 3, 5-di-tert-butyl-4-hydroxyphenyl pharmacophore: dual inhibitors of cyclooxygenases and lipoxygenases, Bioorg. Med. Chem., 14, 5340, 10.1016/j.bmc.2006.03.054 Moreau, 2006, Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl) acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases, Bioorg. Med. Chem., 14, 7716, 10.1016/j.bmc.2006.08.008 Nematollahi, 2010, Docking and QSAR studies of novel (E)-3-(4-methanesulfonylphenyl)-2-(aryl) acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases, Int. J. ChemTech Res., 2, 1808 Orlando, 2016, Substrate-selective inhibition of cyclooxygeanse-2 by fenamic acid derivatives is dependent on peroxide tone, J. Biol. Chem., 291, 15069, 10.1074/jbc.M116.725713 Orlando, 2015, The structure of ibuprofen bound to cyclooxygenase-2, J. Struct. Biol., 189, 62, 10.1016/j.jsb.2014.11.005 Osher, 2006, The 5 lipoxygenase system in the vasculature: emerging role in health and disease, Mol. Cell. Endocrinol., 252, 201, 10.1016/j.mce.2006.03.038 Özadalı, 2012, Synthesis and biological evaluation of isoxazolo [4, 5-d] pyridazin-4-(5H)-one analogues as potent anti-inflammatory agents, Bioorg. Med. Chem., 20, 2912, 10.1016/j.bmc.2012.03.021 Pereira-Leite, 2016, Nonsteroidal anti-inflammatory therapy: a journey toward safety, Med. Res. Rev. Pommery, 2004, New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy, J. Med. Chem., 47, 6195, 10.1021/jm0407761 Pontiki, 2011, Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities, Eur. J. Med. Chem., 46, 191, 10.1016/j.ejmech.2010.10.035 Prasher, 2016, Identification of triazole bridged amino acids appended indoles as dual inhibitors of 5-LOX and COX-2 enzymes, Int. J. ChemTech Res., 9, 453 Praveen Rao, 2006, Synthesis and structure-activity relationship studies of 1, 3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases, J. Med. Chem., 49, 1668, 10.1021/jm0510474 Rao, 2005, Synthesis and biological evaluation of 1, 3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases, Bioorg. Med. Chem. Lett., 15, 4842, 10.1016/j.bmcl.2005.07.036 Revathi, 2006, Rationalization of physicochemical characters of 1, 5-diarylpyrazole analogs as dual (COX-2/LOX-5) inhibitors: a QSAR approach, J. Pharm. Biomed. Anal., 42, 283, 10.1016/j.jpba.2006.04.020 Ricciotti, 2011, Prostaglandins and inflammation, Arterioscler. Thromb. Vasc. Biol., 31, 986, 10.1161/ATVBAHA.110.207449 Rouzer, 2011, Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways, Chem. Rev., 111, 5899, 10.1021/cr2002799 Samuelsson, 1983, The leukotrienes: mediators of immediate hypersensitivity reactions and inflammation, 15 Santos, 2017, 2, 3-Diarylxanthones as potential inhibitors of arachidonic acid metabolic pathways, Inflammation, 1 Sathya, 2014, Anti-oxidant and anti-inflammatory activities of synthetic 2, 4-bis (aryl/heteroaryl)-5-acylthiazole derivatives, Asian J. Biochem. Pharm. Res., 4, 316 Scholz, 2008, Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4, 5-diaryl isoselenazoles, Eur. J. Med. Chem., 43, 1152, 10.1016/j.ejmech.2007.09.007 Scholz, 2009, Diaryl-dithiolanes and-isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, OH scavenging and anti-adhesive activities, Bioorg. Med. Chem., 17, 558, 10.1016/j.bmc.2008.11.074 Shanmugam, 2007, The effect of 1-furan-2-yl-3-pyridine-2-yl-propenone on pharmacokinetic parameters of warfarin, Arch. Pharm. Res., 30, 898, 10.1007/BF02978843 Sharma, 2010, Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids, Mol. Pharmacol., 77, 979, 10.1124/mol.109.063115 Shen, 2017, Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX, Bioorg. Med. Chem. Lett., 27, 3653, 10.1016/j.bmcl.2017.07.020 Shi, 2011, Dual inhibition of 5-LOX and COX-2 suppresses esophageal squamous cell carcinoma, Cancer Lett., 309, 19, 10.1016/j.canlet.2011.05.010 Shrivastava, 2017, Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity, Bioorg. Med. Chem., 10.1016/j.bmc.2017.06.027 Simmons, 2004, Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition, Pharmacol. Rev., 56, 387, 10.1124/pr.56.3.3 Singh, 2015, Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: dual inhibition of 5-LOX and COX-2 enzymes, Eur. J. Med. Chem., 97, 104, 10.1016/j.ejmech.2015.04.044 Singh, 2015, Triblock conjugates: identification of a highly potent antiinflammatory agent, J. Med. Chem., 58, 5989, 10.1021/acs.jmedchem.5b00952 Smith, 2002, The eicosanoids: cyclooxygenase, lipoxygenase, and epoxygenase pathways, New Compr. Biochem., 36, 341, 10.1016/S0167-7306(02)36015-0 Smith, 2000, Cyclooxygenases: structural, cellular, and molecular biology, Annu. Rev. Biochem., 69, 145, 10.1146/annurev.biochem.69.1.145 Smith, 2011, Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis, Chem. Rev., 111, 5821, 10.1021/cr2002992 Taggart, 1982, Fatal cholestatic jaundice in elderly patients taking benoxaprofen, Br. Med. J. (Clin. Res. Ed.), 284, 1372, 10.1136/bmj.284.6326.1372 Tan, 2011, Design, synthesis and biological evaluation of benzo [1.3. 2] dithiazolium ylide 1, 1-dioxide derivatives as potential dual cyclooxygenase-2/5-lipoxygenase inhibitors, Bioorg. Med. Chem., 19, 6316, 10.1016/j.bmc.2011.09.003 Tischler, 1985, L-652,343: a novel dual 5-lipoxygenase/cyclooxygenase inhibitor, Adv. Prostaglandin Thromboxane Leukot. Res., 16, 63 Ulbrich, 2002, Cyclooxygenase-1/2 (COX-1/COX-2) and 5-lipoxygenase (5-LOX) inhibitors of the 6, 7-diaryl-2, 3-1H-dihydropyrrolizine type, Eur. J. Med. Chem., 37, 953, 10.1016/S0223-5234(02)01418-6 Vane, 2000, The mechanism of action of anti-inflammatory drugs, 1 Vecchio, 2010, Structural basis of fatty acid substrate binding to cyclooxygenase-2, J. Biol. Chem., 285, 22152, 10.1074/jbc.M110.119867 Wallace, 1993, Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy, Gastroenterology, 105, 1630, 10.1016/0016-5085(93)91057-O Weisman, 1994, Effects of tebufelone (NE-11740), a new anti-inflammatory drug, on arachidonic acid metabolism, Agents Actions, 41, 156, 10.1007/BF02001910 Whelton, 1991, Nonsteroidal anti-inflammatory drugs: effects on kidney function, J. Clin. Pharmacol., 31, 588, 10.1002/j.1552-4604.1991.tb03743.x Willerson, 2004, Inflammation as a cardiovascular risk factor, Circulation, 109, II-2 Wolfe, 1999, Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs, N. Engl. J. Med., 340, 1888, 10.1056/NEJM199906173402407 Wong, 1992, Antiarthritic profile of BF-389—a novel anti-inflammatory agent with low ulcerogenic liability, Agents Actions, 37, 90, 10.1007/BF01987895 Xu, 2009, Anti-inflammatory effects and gastrointestinal safety of NNU-hdpa, a novel dual COX/5-LOX inhibitor, Eur. J. Pharmacol., 611, 100, 10.1016/j.ejphar.2009.03.062 Xu, 2009, Biological evaluation of 2-(4-amino-phenyl)-3-(3, 5-dihydroxylphenyl) propenoic acid, Basic Clin. Pharmacol. Toxicol., 105, 350, 10.1111/j.1742-7843.2009.00463.x Xu, 2013, Inhibition of inflammatory mediators contributes to the anti-inflammatory activity of KYKZL-1 via MAPK and NF-κB pathway, Toxicol. Appl. Pharmacol., 272, 221, 10.1016/j.taap.2013.05.025 Xu, 2014, Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding network, J. Biol. Chem., 289, 6799, 10.1074/jbc.M113.517987 Yang, 2007, Dynamic simulations on the arachidonic acid metabolic network, PLoS Comput. Biol., 3, 10.1371/journal.pcbi.0030055 Yu, 2010, Synthesis and biological evaluation of N-difluoromethyl-1, 2-dihydropyrid-2-one acetic acid regioisomers: dual inhibitors of cyclooxygenases and 5-lipoxygenase, Bioorg. Med. Chem. Lett., 20, 2168, 10.1016/j.bmcl.2010.02.040 Zheng, 2006, Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues, Bioorg. Med. Chem., 14, 3428, 10.1016/j.bmc.2005.12.062 Zimmermann, 2007, Multi-target therapeutics: when the whole is greater than the sum of the parts, Drug Discov. Today, 12, 34, 10.1016/j.drudis.2006.11.008